ProShare Advisors’s ArriVent BioPharma AVBP Stock Holding History

ProShare Advisors’s Portfolio AVBP Stock Details AVBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-9,532	Closed	-$254K	–	2256
2024 Q4	$254K	Buy	+9,532	New	+$274K	﹤0.01%	1756

Other funds holding AVBP

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

IAM

Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ProShare Advisors's AVBP Position: Q1 2025 in Review

ProShare Advisors sold out of ArriVent BioPharma (AVBP) in Q1 2025, closing a stake of 9,532 shares — an estimated $254K sold.

ProShare Advisors first reported a position in AVBP in Q4 2024 and held it in 1 quarter. The position peaked at $254K in Q4 2024. 83 funds tracked by Wall St. Rank hold AVBP as of Q1 2025.

ProShare Advisors reported no remaining ArriVent BioPharma position as of Q1 2025 after selling out during the quarter.
ProShare Advisors sold 9,532 ArriVent BioPharma shares in Q1 2025, an estimated $254K.
ProShare Advisors first reported a position in ArriVent BioPharma in Q4 2024 and held it in 1 quarter.
ProShare Advisors's ArriVent BioPharma position peaked at $254K in Q4 2024.
83 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2025.

Based on ProShare Advisors's 13F filing for Q1 2025, filed 8 May 2025.